Gut Microbes May Have an Association With Toxicity Related to Combination Immune Checkpoint Inhibitors in Advanced Melanoma
Source: cancer network, August 2021
Specific intestinal microbiota signatures appear to have an association with high-grade adverse effects (AEs) and responses to CTLA-4/anti–PD-1 combination therapy in patients with advanced melanoma, according to the results of a study published in Nature Medicine.1
